Infection and contamination control company Tristel has reported a pre-tax profit of £650,000 for the 26 week period ended 31 December 2009.

The company’s profits increased by 39.9% from £469,000 in 2008, while gross profit rose by 24.1% to £2.5 million.

Revenue at Tristel climbed by 28% to just over £4 million.

House broker Fincap commented: “Tristel’s shares are under valued and we believe a share price of 76 pence as a share price would bring it more in line with its peers.

Paul Swinney, chief executive of Tristel, said: “The first half has seen yet another strong performance from the Group. Integrating the manufacture of the Medichem portfolio of disinfectants, which we acquired on 3 July, has been challenging, but successful and has made a significant contribution to top line growth. 

“Our Tristel products have continued to win new hospital customers in the United Kingdom and overseas, with overseas sales increasing by 20% on the comparable period last year.

“Reflecting our continuing progress we are pleased to announce the payment of an interim dividend of 0.425 pence, a 5% increase on last year.”